The data looks disappointing enough. 1 PR out of 55 evaluable patients and the rest a smattering of SD. Similarly CALA drops 21% today. Again 1 PR out of 77 evaluable patients and a smattering of SD. http://finance.yahoo.com/news/calithera-present-phase-1-solid-171500235.html FWIW, CALA market cap is 34M vs AGIO 2.4B I don't have any position in either company.